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Protein Losing Enteropathy following Fontan Palliation in the Single Ventricle Population
Alaina Dunkelberger, RN, BSN, CCRN
Otterbein University, Westerville, Ohio
Review of Single Ventricle Surgical Management
Congenital heart defects requiring single
ventricle palliation are a rare but lifethreatening occurrence. There are
multiple defects resulting in single
ventricle physiology including defects in
which the right or left ventricle within the
heart is either undeveloped (hypoplastic
left heart syndrome, hypoplastic right
heart syndrome), or the valve to the main
pulmonary artery did not form (pulmonary
atresia). These defects prevent the heart
from supplying adequate blood flow to the
lungs or body. Single ventricle congenital
heart defects are not easily treated
surgically due to their complexity in
nature. Single ventricle surgical palliation
typically involves three open-heart
surgeries including the Norwood or
Hybrid Procedure, the Bidirectional Glenn
procedure, and finally the Fontan
procedure, (Hardiman, 2013, p. 327).

Figure 1. Hypoplastic Left Heart Syndrome
anatomy (left). Norwood procedure anatomy
(right).

Figure 2. Hybrid procedure circulation.

Traditional Three
Stage Single Ventricle
Palliation

The Norwood procedure is the traditional
operation performed during the neonatal
period. This procedure converts the single
operating ventricle into the main pumping
chamber for both systemic and pulmonary
blood flow. The pulmonary artery and aorta
are combined, removing the main pulmonary
artery from the branching pulmonary
arteries. A shunt is placed between the neoaorta and the pulmonary arteries to provide
blood flow to the lungs, (Hardiman, 2013, p.
327).
Nationwide Children’s Hospital in Columbus,
Ohio, often performs the GalantowiczCheetham Procedure, also known as the
Hybrid procedure, in place of the Norwood
procedure. This procedure entails bands
being placed around the pulmonary arteries
to reduce pulmonary blood flow which
encourages shunting back into the systemic
system. A stent is then placed in the patent
ductus arteriosus to maintain mixed
oxygenated and deoxygenated blood being
delivered to the body. Finally, a balloon atrial
septostomy is performed to allow for more
mixing of oxygenated and deoxygenated
blood.This procedure requires less
manipulation of the heart than the Norwood
procedure and also allows the child to avoid
cardiopulmonary bypass (Rowland, et al.,
2008.)
The Bi-directional Glenn is performed four to
six months after the Norwood procedure.
The shunt between the pulmonary artery and
the aorta is removed. The superior vena cava
is then connected directly to the right
pulmonary artery. This connection brings
deoxygenated blood from the upper half of
the body passively to the lungs, bypassing the
right ventricle. (Hardiman, 2013, p. 327).
The Fontan operation is typically
performed18-24 months after the bidirectional Glenn procedure. The inferior
vena cava is connected to the right
pulmonary artery. This, combined with the
bi-directional Glenn, allows for all
deoxygenated blood to flow passively to the
lungs. The single ventricle is now only
providing systemic perfusion (Hardiman,
2013, p. 328).

Figure 3. Bidirectional Glenn anatomy (left).
Intracardiac fontan anatomy (middle).
Extracardiac fontan anatomy (right).

Protein-Losing
Enteropathy
Protein-losing enteropathy (PLE) is a
rare but serious condition that can occur
following Fontan palliation. This disease
occurs when protein from the body is
“lost” or leaking into the intestinal tract.
Hypoalbuminemia in generally the first
indication of PLE (Sathiyasekaran, 2013).
Diagnosis is then confirmed by the
presence of fecal alpha 1-antitrypsin,
proving the existence of blood protein
below the pylorus in the gastrointestinal
tract (Braampskamp, Dolman, &
Tabbers, 2010).
PLE is said to occur in approximately 3–
15% of patients after the Fontan
operation and carries a high risk of
mortality (Umar & DuBaise, 2009). Five
and ten year survival rates after PLE
diagnosis following the Fontan surgery
were noted to be 48% and 30%
respectively (Umar & DuBaise, 2009).

Theories on the Pathophysiology behind
Protein-Losing Enteropathy
The pathophysiology of the development of protein-losing enteropathy has not been
precisely determined but several theories exist. The lymphatic and cardiovascular system are
closely related; elevated central venous pressures increases lymphatic production while
simultaneously slowing lymphatic return (Meadows & Jenkins, 2011, p. 373). One theory is
that the increased systemic venous pressures related to the passive blood flow to the
pulmonary artery causes dilation of the lymphatic system within the gastrointestinal tract
leading to leakage of protein into the gastrointestinal system (Umar & DiBaise, 2009). A
second theory is the elevated systemic venous pressure alongside the impaired cardiac
output from a single ventricle state combine to impair perfusion and oxygenation to the
gastrointestinal system (Umar & DiBaise, 2009). The impaired blood flow and ischemia
compromises the epithelium and leads to protein leaking into the lumen. “Gross and
microscopic pathologic examination of the intestine in patients with protein-losing
enteropathy demonstrates several characteristic findings consistent with lymphatic
engorgement, stasis and insufficiency,” (Meadows & Jenkins, 2011, p. 369). A third theory
suggests that the chronic low cardiac output state of a person with single ventricle circulation
causes inflammation; cytokines cause vasoconstriction and have been found at elevated
levels immediately after Fontan palliation which is not surprising, but a study in 2006 found
elevated cytokine levels years after the procedure (Ostrow, Freeze, & Rychik, 2006, p. 698).
The pathophysiologic significance of these findings lies in the fact that there is no definitive
causative source leading to the development of protein-losing enteropathy. The lack of a
determined underlying cause creates difficulty for providers attempting to medically manage
this population.

Medical
Management of
Protein-Losing
Enteropathy
Management of protein-losing enteropathy
has proven to be inadequate for patients and
frustrating for healthcare professionals.
Supportive measures include dietary
modifications (high protein, low fat), diuretics
including Lasix and spironolactone, and
intermittent albumin infusions (Braamskamp,
Dolman, & Tabbers, 2009, p. 1183).

Nursing Implications
Nursing implications for protein-losing
enteropathy are multi-faceted. The nurse
should provide emotional support for the
patient and their family. PLE is typically a
chronic, fatal condition so the diagnosis
can be devastating. The nurse can improve
the experience for the patient and family
by advocating for early palliative care
involvement. There are several ethical
issues revolving around the care of the
single ventricle population, “…Because the
neonate is incapable of participating in the
decision-making process, the nurse must
advocate for the child adequately and
succinctly explaining all facets of each of
the available treatment options to the
parents,” (Zeigler, 2003, p. 69). The nurse
is responsible for the proper
administration of prescribed therapies and
educating the patient and/or their families
on their use. The patient should be closely
monitored for worsening symptoms,
specifically respiratory failure related to
ascites or pleural effusions. The nurse
should be prepared to intervene in a
medical emergency such as cardiac
tamponade from a pericardial effusion. .

More specific treatment includes heparin
therapy which has shown limited success
(Meadows & Jenkins, 2011, p. 371). Heparin’s
mechanism of action in aiding in the resolution
of PLE is unclear. A deficiency of enterocyte
heparin in patients that showed success with
heparin therapy has been suggested
(Meadows & Jenkins, 2011, p. 371).
Corticosteroids have been used as well with
some limited success with 2-3 weeks of
treatment, the mechanism of action in the
disease remains unclear but is thought to be
related to its anti-inflammatory effects
(Meadows & Jenkins, 2011, p. 371). Adrenal
suppression has been commonly found among
patients with PLE, often requiring stress-doses
of corticosteroids (Goldberg, Dodds, & Rychik,
Braamskamp, M., Dolman, K., & Tabbers, M.
2011, p. 79).
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Risk Factors for
Developing PLE
Pre-operative risk factors indicated
include having a hypoplastic left
ventricle and increased end-diastolic
pressures. Longer operative times have
been indicated in the development of
PLE post-operatively. Post-operative
echocardiograms showing a reduced
ventricular area have been linked with
the development of PLE (Umar &
DuBaise, 2009). Post-operative renal
failure is also related to the
development of PLE in the future
(Meadows & Jenkins, 2011, p. 370).

Figure 4. Depiction of the development of protein-losing enteropathy
related to lymphatic and venous obstruction.

Clinical Manisfestations of Protein-Losing
Enteropathy
The loss of protein into the gastrointestinal tract creates many life-altering and lifethreatening clinical manifestations. Patients with PLE can become severely edematous which
can inhibit respiration. Diarrhea may occur causing electrolyte imbalances as well as
dehydration. Ascites develops as the leaking of protein continues; it can eventually become
severe enough to cause discomfort and difficulty breathing, requiring abdominal paracentesis.
Pleural effusions are a common occurrence in patients with PLE, requiring the placement of
chest tubes or even chemical or surgical pleurodesis. Pericardial effusions can also occur
which have the potential to become life-threatening (Caltepe & Comba, 2013).
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